<DOC>
	<DOC>NCT01470599</DOC>
	<brief_summary>The study hypothesis is to establish the safety and tolerability of long-term open-label (OL) CP-690,550 therapy in subjects with Crohn's disease.</brief_summary>
	<brief_title>A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Subjects who complete 26week maintenance treatment of the A3921084 study or subjects who withdraw early due to A3921084 study treatment failure (see Appendix 5). Women of childbearing potential must test negative for pregnancy prior to study enrolment. Sexually active females of childbearing potential are required to use adequate contraceptive methods during the study period and until completion of the followup procedures. No specific contraceptive measures are required in male subjects during study participation. Subjects who have been discontinued due to protocol violation(s) (as determined by the Sponsor) in the A3921084 study. Subjects who were discontinued from the A3921084 study due to an adverse event. Subjects likely to require any nonelective surgery or surgery requiring overnight stay (with the exception of minor same day outpatient procedures that will not interfere with study drug dosing).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>